Indonesia says to secure Sinopharm COVID-19 vaccine for private use

BPOM did not respond to a request for comment. At the same forum, State-owned enterprises minister Erick Thohir said more than 6,600 companies had signed up for the private scheme, which some health experts have criticised because of concern it could worsen vaccine inequity.

Reuters | Jakarta | Updated: 25-02-2021 11:07 IST | Created: 25-02-2021 11:07 IST
Indonesia says to secure Sinopharm COVID-19 vaccine for private use

Indonesia will receive at least two million doses of a coronavirus vaccine produced by China's Sinopharm for use in a private vaccination scheme due to run alongside a national inoculation programme, a minister said on Thursday. Indonesia, which has faced one of the biggest COVID-19 outbreaks in Asia, aims to vaccinate 181.5 million people within about a year using vaccines made by companies such as Sinovac Biotech, Novavax and AstraZeneca.

Luhut Binsar Pandjaitan, Indonesia's minister for maritime affairs and investment, said the China National Pharmaceutical Group (Sinopharm) vaccine would be part of the private scheme. "What's fixed is two million (doses). Three million is our hope...we will vaccinate employees in stages," he told an economic forum.

The private plan has been pushed by Indonesian business as a way for companies to buy vaccines from the government so that their employees can be vaccinated in order to help prop up the country's battered economy. The private plan is due to use alternative vaccines from the ones currently being used and the government is preparing a regulation.

Bambang Heriyanto, corporate secretary of Bio Farma, a state-owned pharmaceutical company in charge of procuring vaccines, said talks were still ongoing with Sinopharm and the vaccine needed approval from the food and drugs agency (BPOM). BPOM did not respond to a request for comment.

At the same forum, State-owned enterprises minister Erick Thohir said more than 6,600 companies had signed up for the private scheme, which some health experts have criticised because of concern it could worsen vaccine inequity. Sinopharm did not immediately respond to a request for comment.

Sinopharm affiliate, the Wuhan Institute Of Biological Products, said on Wednesday its vaccine had an efficacy rate of 72.51% against COVID-19, citing interim analysis of late-stage clinical trial data, without offering more details.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Viral variants and vaccine nationalism pose two-pronged threat to Covid victory

... ...

Tracking Fintech during COVID-19: Harnessing power of technology

Its abundantly clear now that as fintech cements its place in the financial sector, accelerated further by the COVID-19 pandemic, it could open the sector to new possibilities by harnessing the power of technology to deliver financial ...

Tectonic turns: How technology shaped healthcare over the decades

Tracing an episodic evolution, with technology at the interface of human and his health....

World Water Day sees crises of inequality in countries both rich and poor

... ...

Videos

Latest News

China's March exports to North Korea spike to six-month high

Chinas exports to North Korea in March rose to a six-month high, with outbound shipments to its neighbour that month nearly 400 times more than January-February combined, in a sign of easing border restrictions imposed due to COVID-19. Chin...

Police in Texas hunting former deputy sheriff after triple homicide

Police in Austin, Texas, were searching on Sunday for a former deputy sheriff wanted in connection with the fatal shooting of three people at an apartment complex earlier in the day.The slayings, which followed a spate of mass shootings in ...

LG Uplus partners with Nokia to expand 5G coverage in South Korea

Nokia on Monday announced the signing of an agreement with LG Uplus to expand and enhance the latters 5G network in South Korea, enabling seamless 5G connectivity between indoor and outdoor locations.We are delighted to have been chosen by ...

US: Authorities say no one was driving Tesla before deadly crash

Two people were killed in the fiery crash of a Tesla and authorities say there was no one in the drivers seat, although it is not clear whether the cars driver-assist system was being used.A Harris County constable told television stations ...

Give Feedback